Blueprint Medicines Corporation (LON:0HOJ)

Market Cap	4.13B
Revenue (ttm)	406.43M
Net Income (ttm)	-53.59M
Shares Out	n/a
EPS (ttm)	-0.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23
Average Volume	108
Open	86.38
Previous Close	84.27
Day's Range	84.70 - 86.38
52-Week Range	42.68 - 100.99
Beta	n/a
RSI	48.41
Earnings Date	May 2, 2025

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medul...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2008
• Employees: 649
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HOJ

Financial Performance

In 2024, Blueprint Medicines's revenue was $508.82 million, an increase of 104.04% compared to the previous year's $249.38 million. Losses were -$67.09 million, -86.77% less than in 2023.

Financial numbers in USD